JNJJanssen Research & Development, LLCRunning, no new patients
A Study of Erdafitinib in Participants With Metastatic or Locally Advanced Urothelial Cancer
Urothelial Carcinoma
2Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
- +2
4 insiders sold shares within a month
Since Aug 17, 2026 · was worth 5, fading over time
Worry score2
Score over time
- Stage
- Phase 1/2
- Patients
- 125 (final count)
- Started
- Apr 5, 2018
- Main results expected
- Sep 30, 2022
- Fully finished
- Dec 31, 2026
- Results posted
- Oct 25, 2023
What counts as success
The trial's main goal(s), called the “primary outcome.”
Phase 1b: Number of Participants With Dose-Limiting Toxicity (DLTs)
Measured over: Up to 8 weeks
Phase 2: Objective Response Rate (ORR) Per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 by Investigator Assessment
Measured over: From Day 1 up to 36 months
Phase 2: Number of Participants With Treatment-emergent Adverse Event (TEAEs)
Measured over: From Day 1 up to 36 months
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- insider_selling_cluster: base 5, now 2, since 2026-08-17, fades (half-life)
Raw record changes
- none yet
Trial ID NCT03473743 · record last updated 2026-08-28 · checked 2026-11-09 15:47 UTC